• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    YMCA of the USA Deepens Collaboration with DaVita to Drive Kidney Health Initiatives in Seven Communities

    2/27/25 9:00:00 AM ET
    $DVA
    Misc Health and Biotechnology Services
    Health Care
    Get the next $DVA alert in real time by email

    CHICAGO and DENVER, Feb. 27, 2025 (GLOBE NEWSWIRE) -- YMCA of the USA (Y-USA), the national resource office for the 2,600+ YMCAs across the country, is excited to expand its collaboration with DaVita, a leading provider of comprehensive kidney care, to advance chronic disease education and prevention for individuals and their families who are either managing or at risk for chronic kidney disease (CKD). CKD disproportionately affects individuals with risk factors such as hypertension and diabetes.

    Following an investment from the DaVita Giving Foundation, Y-USA and DaVita will collaborate to further close the kidney health education gap, empower early risk detection and connect individuals with preventive care resources. Seven Y locations across the country will take part in the Collaborative Community Kidney Health Program (CCKHP), aiming to raise awareness of CKD risk factors, provide chronic disease screenings and connect communities at risk with essential kidney health education and resources. The goal is to impact more than 3,000 individuals over the next two years.

    The CCKHP began with a pilot program at the Capital Area YMCA (Baton Rouge, LA), which included a screening event that welcomed more than 150 attendees to learn more about their kidney health. Now, Y-USA and DaVita will expand this effort across select communities disproportionately affected by risk factors. The joint strategy will continue to educate communities on addressing risk factors through resources and screenings that can facilitate more proactive care interventions — aiming to reduce the occurrence of preventable kidney disease.

    "We are excited to collaborate with DaVita to bring life-changing kidney health educational resources directly into communities that need them most," said Heather Hodge, Vice President of Emerging Opportunities at Y-USA. "By leveraging the Y's trusted resources and DaVita's expertise, we are taking a significant step toward healthier communities."  

    "Broader access to preventive kidney health demands widespread collaboration across communities," said Liz Gardner, executive director of the DaVita Giving Foundation. "By joining forces with Y-USA, we're committed to enabling broader access to essential resources, including health education, screenings and community support to foster healthier lives."

    The seven Y locations participating in this program include:

    • Capital Area YMCA (LA) - pilot
    • Jackson Metropolitan YMCA (MS)
    • Tampa Metropolitan YMCA (FL)
    • YMCA of Greater Cincinnati (OH)
    • YMCA of Metropolitan Atlanta (GA)
    • YMCA of Metropolitan Denver (CO)
    • YMCA of Metropolitan Los Angeles (CA)

    The program will equip participants and their families with skills, resources and access to vital information about preventing chronic diseases, while also helping individuals take greater control of their own health. Program activities have been divided into three components:

    1. Kidney Health Education: Y-USA will collaborate with DaVita and other public health organizations to provide flexible kidney health education resources to Ys, allowing each location to tailor activities based on community needs and capacity.



    2. Kidney Health Screening: Over the coming two years, select Ys will host screening events with DaVita and local partner support, building capacity in the first year and expanding reach in the second year, with variations in capacity based on market size and location.



    3. Community-Based Referral Resources: Each participating Y location will offer a catalogue of Y and community resources to support improved health, provide referrals to Y programs such as the YMCA's Blood Pressure Self-Monitoring Program and YMCA's Diabetes Prevention Program, and connect screening participants to health support services.

    About the Y

    Driven by its founding mission, the Y has served as a leading nonprofit committed to strengthening community for more than 175 years. The Y empowers everyone, no matter who they are or where they're from, by ensuring access to resources, relationships, and opportunities for all to learn, grow and thrive. By bringing together people from different backgrounds, perspectives and generations, the Y's goal is to improve overall health and well-being, ignite youth empowerment and demonstrate the importance of connections in and across 10,000 communities nationwide. Learn more at ymca.org.

    About DaVita Inc.

    DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of December 31, 2024, DaVita served approximately 281,100 patients at 3,166 outpatient dialysis centers, of which 2,657 centers were located in the United States and 509 centers were located in 13 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

    Contact:

    YMCA of the USA

    312-419-8418

    [email protected]



    Primary Logo

    Get the next $DVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DVA

    DatePrice TargetRatingAnalyst
    3/6/2024$133.00Equal Weight
    Barclays
    8/7/2023$100.00 → $142.00Neutral → Buy
    UBS
    11/1/2022$97.00 → $72.00Buy → Hold
    Deutsche Bank
    10/31/2022$117.00 → $74.00Buy → Neutral
    UBS
    8/19/2022$106.00 → $117.00Buy
    UBS
    6/21/2022$110.00 → $90.00Underperform
    BofA Securities
    1/5/2022$114.00 → $125.00Hold
    Truist Securities
    10/29/2021$113.00 → $111.00Sector Perform
    RBC Capital
    More analyst ratings

    $DVA
    Leadership Updates

    Live Leadership Updates

    See more
    • DaVita Appoints Jessica Hergenreter as Chief People Officer

      DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C

      10/17/24 1:00:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Appoints David Maughan New Chief Operating Officer, Mike Staffieri Steps into Emeritus Role

      DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on

      9/13/24 8:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Appoints New Chief Information Officer

      Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita  DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),

      5/13/24 9:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Financials

    Live finance-specific insights

    See more
    • DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

      DENVER, April 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Monday, May 12, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Monday, May 12, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the

      4/30/25 11:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. 4th Quarter 2024 Results

      DENVER, Feb. 13, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended December 31, 2024. "Despite a year with unique hurdles, we finished strong in 2024, producing full year adjusted operating income and adjusted EPS in the top half of our guidance range," said Javier Rodriquez, CEO of DaVita Inc. "As we embark on 2025, when we will be celebrating the 25th anniversary of DaVita, we look forward to continuing our efforts to improve clinical outcomes, enhance quality of life for our patients and teammates, and be a force for positive change in the healthcare system." Financial and operating highlights for the quarter and year ended Decembe

      2/13/25 4:05:00 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call

      DENVER, Jan. 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE: DVA), announced today that it will hold its quarterly conference call to discuss fourth quarter results on Thursday, February 13, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Thursday, February 13, 2025Starting at 5:00 p.m. ESTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to

      1/30/25 11:55:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

      SC 13G/A - DAVITA INC. (0000927066) (Subject)

      2/13/24 5:02:42 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by DaVita Inc. (Amendment)

      SC 13G/A - DAVITA INC. (0000927066) (Subject)

      2/9/22 3:43:35 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by DaVita Inc. (Amendment)

      SC 13D/A - DAVITA INC. (0000927066) (Subject)

      8/4/21 4:02:59 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    SEC Filings

    See more
    • SEC Form DEFA14A filed by DaVita Inc.

      DEFA14A - DAVITA INC. (0000927066) (Filer)

      4/24/25 5:20:43 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form DEF 14A filed by DaVita Inc.

      DEF 14A - DAVITA INC. (0000927066) (Filer)

      4/24/25 5:18:43 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 8-K filed by DaVita Inc.

      8-K - DAVITA INC. (0000927066) (Filer)

      4/14/25 6:54:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barclays initiated coverage on DaVita with a new price target

      Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00

      3/6/24 8:09:27 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita upgraded by UBS with a new price target

      UBS upgraded DaVita from Neutral to Buy and set a new price target of $142.00 from $100.00 previously

      8/7/23 7:20:56 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded DaVita from Buy to Hold and set a new price target of $72.00 from $97.00 previously

      11/1/22 9:18:39 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

      DENVER, April 30, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss first quarter results on Monday, May 12, 2025, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows:  Monday, May 12, 2025Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen to the

      4/30/25 11:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • DaVita Inc. to Participate in the Barclays Global Healthcare Conference 2025

      DENVER, March 6, 2025 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at the Barclays Global Healthcare Conference 2025 on Tuesday, March 11, 2025, at 9:00 a.m. EDT. To view the live webcast, visit the Barclays page and create a free registration. About DaVita Inc. DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares fo

      3/6/25 10:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • YMCA of the USA Deepens Collaboration with DaVita to Drive Kidney Health Initiatives in Seven Communities

      CHICAGO and DENVER, Feb. 27, 2025 (GLOBE NEWSWIRE) -- YMCA of the USA (Y-USA), the national resource office for the 2,600+ YMCAs across the country, is excited to expand its collaboration with DaVita, a leading provider of comprehensive kidney care, to advance chronic disease education and prevention for individuals and their families who are either managing or at risk for chronic kidney disease (CKD). CKD disproportionately affects individuals with risk factors such as hypertension and diabetes. Following an investment from the DaVita Giving Foundation, Y-USA and DaVita will collaborate to further close the kidney health education gap, empower early risk detection and connect individuals

      2/27/25 9:00:00 AM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care

    $DVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Rodriguez Javier was granted 18,822 shares, increasing direct ownership by 2% to 894,080 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      3/18/25 7:42:51 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • Chief Compliance Officer Hearty James O was granted 1,185 shares and covered exercise/tax liability with 2,319 shares, decreasing direct ownership by 4% to 28,389 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      3/18/25 7:42:41 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care
    • Director Pullin Dennis W was granted 349 shares, increasing direct ownership by 57% to 961 units (SEC Form 4)

      4 - DAVITA INC. (0000927066) (Issuer)

      3/18/25 7:42:31 PM ET
      $DVA
      Misc Health and Biotechnology Services
      Health Care